| Table V.5: The Number of States Reporting Challenges Regarding Communication or Interactions with the Food and Drug Administration (FDA) Related to Drug Compounding Issues | |||
|---|---|---|---|
| Number of states (%) | |||
| Yes: state has experienced challenges | No: state has not experienced any challenges | N/A: state has not had any communication or interactions with FDA related to drug compounding issues | No response |
| 15 (30) | 25 (50) | 8 (16) | 2 (4) |
| Source: GAO survey of state pharmacy regulatory bodies, survey question 33. | GAO-17-363SP |
| Note: GAO surveyed the state pharmacy regulatory bodies in the 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands, and all but 4 completed the survey. |